CANF // Can-Fite Biopharma Ltd each representing two (2)
FA <GO> NYSE RQD COCKPIT → CIK 0001536196 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$1.66 ▲ +0.01
(+0.61%)
MKT CAP: $5.0M • VOL: 22.0K
52W L $2 52W H $12
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
CANF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $405.0K | $674.0K | $743.0K |
| YoY Revenue Growth % | -39.9% | -9.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.9M | -$8.1M | -$8.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$9.8M | -$7.9M | -$7.6M |
| EBITDA (Normalized) | -$9.9M | -$8.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.9M | -$7.6M | -$8.4M |
| Capital Expenditures (CapEx) | $2.0K | $5.0K | — |
| Free Cash Flow (FCF) | -$9.0M | -$7.6M | -$8.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.5M | $4.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.6M | $5.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CANF.